Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced Sinonasal Carcinoma

NCT05925491 is registered in ClinicalTrials.gov with Istituti Clinici Scientifici Maugeri SpA as lead sponsor.

NCT NCT05925491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05925491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced Sinonasal Carcinoma
Lead sponsor
Istituti Clinici Scientifici Maugeri SpA
Phase
Phase 2
Overall status
Recruiting
Start date
December 24, 2024
Completion date
December 31, 2027
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sinonasal undifferentiated carcinoma